Blocking the CB1 Cannabinoid Receptor Reduced Adolescent Binge Drinking in Mice Without Affecting Adults | Research

The takeaway

A CB1 receptor blocker reduced alcohol binge drinking in adolescent mice to adult levels without changing adult intake, suggesting developmental differences in the endocannabinoid system may drive age-related drinking patterns.

Readers interested in why adolescents are more prone to binge drinking and what brain systems are involved.

CB1 blocker reduced adolescent binge drinking to adult levels without affecting adult intake

What the researchers found

Researchers gave adolescent and adult mice access to alcohol or sucrose in a binge-drinking paradigm. Adolescent mice consumed more of both substances compared to adults, consistent with what is observed in human adolescents.

Pre-treatment with AM-251, a CB1 receptor antagonist, dose-dependently reduced adolescent alcohol consumption down to adult levels without affecting adult intake. The same pattern appeared with sucrose: the drug reduced adolescent but not adult consumption.

The reductions were not explained by changes in locomotor activity or anxiety-like behavior, suggesting a specific effect on reward-driven consumption rather than general behavioral suppression.

Why it matters

Adolescent binge drinking is a major public health concern associated with long-term health consequences. This study identifies the endocannabinoid system, specifically CB1 receptor activity, as a potential mechanism driving increased binge consumption during adolescence compared to adulthood.

The numbers in context

AM-251 at 1, 3, and 10 mg/kg dose-dependently reduced adolescent alcohol consumption. AM-251 at 3 mg/kg reduced adolescent sucrose consumption. Neither dose altered adult consumption of either substance. No changes in locomotor activity or thigmotaxis were observed.

How the study worked

Adolescent and adult male C57BL/6J mice underwent a binge-drinking paradigm with access to 20% alcohol or 1% sucrose for 4 hours every other day. AM-251 was tested at 0, 1, 3, and 10 mg/kg in a Latin square design. Open-field locomotor activity and thigmotaxis (wall-hugging, an anxiety measure) were also assessed.

What this study cannot tell us

This was a mouse study, and the CB1 antagonist AM-251 has known side effects in humans (rimonabant, a similar drug, was withdrawn from the market due to psychiatric side effects). Only male mice were tested. The binge-drinking paradigm, while validated, is a simplified model of human binge drinking.

How to read the evidence

This is an animal study in mice. While the results are consistent and well-controlled, translating to human adolescent behavior and treatment requires substantial further research.

When this study was published

Published in 2016. Research on endocannabinoid system development and adolescent behavior has continued to evolve.

The bigger picture

The finding that CB1 activity specifically drives adolescent-typical binge consumption connects to broader research on how the developing endocannabinoid system shapes adolescent behavior. It may help explain why adolescents are particularly vulnerable to binge drinking and suggests the endocannabinoid system as a potential intervention target.

Questions still open

Could endocannabinoid system differences between adolescents and adults explain other age-related behavioral patterns? Are there safer ways to target CB1 signaling in adolescents to reduce binge drinking risk?

Common questions

Could blocking CB1 receptors reduce binge drinking in human teenagers?

While the concept is intriguing, a similar CB1 blocker (rimonabant) was withdrawn from the European market due to psychiatric side effects including depression and suicidal thoughts. Safer approaches to modulating endocannabinoid signaling would need to be developed before this could be considered for human use.

Does this mean the endocannabinoid system is different in adolescents?

The results suggest that CB1 receptor activity plays a larger role in driving reward-seeking consumption during adolescence than in adulthood. This is consistent with other research showing the endocannabinoid system is still maturing during adolescence.

Read the original research

Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice.

Pharmacology, biochemistry, and behavior, 143, 11-7

View on PubMed ↗Publisher’s paper ↗

Citation

Agoglia, Abigail E; Holstein, Sarah E; Eastman, Vallari R; Hodge, Clyde W. (2016). Cannabinoid CB1 receptor inhibition blunts adolescent-typical increased binge alcohol and sucrose consumption in male C57BL/6J mice.. Pharmacology, biochemistry, and behavior, 143, 11-7. https://doi.org/10.1016/j.pbb.2016.01.009